Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...

Povorcitinib was considered well tolerated with no new safety signals. Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click here to read why INCY is a Buy.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib drug candidate in the chronic, inflammatory skin condition hidradenitis suppurativa. Incyte on ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe ...

Learn about the common myths and misconceptions about hidradenitis suppurativa (HS) and why it is often misdiagnosed.

A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline ...

Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.